Abstracts tagged "methotrexate (MTX)"

Abstract Number: 3090 • 2016 ACR/ARHP Annual Meeting
Inflammation Detected with Modern Sensitive MRI Analysis Demonstrates That Therapeutic Response As Early As One Month Predicts 12-Month Radiographic Progression: Data from a Study Using Tofacitinib and Methotrexate in Early RA
Philip G. Conaghan¹, Michael A Bowes², Mikkel Østergaard³, Gwenael Guillard², Douglass Chapman⁴, Amy Stein⁵, John Andrews⁴, Zhiyong Xie⁶, Andrew Koenig⁷, Koshika Soma⁴ and Bethanie Wilkinson⁶, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Imorphics Ltd, Manchester, United Kingdom, ³Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ⁴Pfizer Inc, New York, NY, ⁵Biostatistics, Quintiles, Morrisville, NC, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. A novel automated quantification method for RA MRI-detected pathology using statistical shape…
Abstract Number: 1204 • 2016 ACR/ARHP Annual Meeting
Methotrexate Is an Antibacterial Drug Metabolized By Human Gut Bacteria
Renuka R. Nayak^1,2, Colleen O'Loughlin³, Michael Fischbach⁴ and Peter J. Turnbaugh⁵, ¹Department of Microbiology & Immunology, University of California, San Francisco, San Francisco, CA, ²Department of Medicine, UCSF, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ³Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, ⁴Department of Bioengineering and Therapeutic Sciences,, University of California, San Francisco, San Francisco, CA, ⁵Microbiology and Immunology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease of unknown etiology that causes inflammation and irreversible damage in joints and other organs. Methotrexate (MTX) is…
Abstract Number: 3151 • 2016 ACR/ARHP Annual Meeting
The Diagnostic and Predictive Value of Anti-Acetylated Peptide Antibodies in RA Patients Starting Methotrexate Treatment
Paul Studenic¹, Stephan Blüml², Holger Bang³, Manuel Unger⁴, Karim Raza⁵, Daniel Aletaha⁶, Josef S. Smolen^7,8 and Günter Steiner⁹, ¹Department of Internal Medicine 3, Division of Rheumatology and Geriatric Medicine, Medical University Vienna, Vienna, Austria, ²Internal Medicine 3; Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Rsearch & Development, Orgentec Diagnostika GmbH, Mainz, Germany, ⁴Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ⁵University of Birmingham, Rheumatology Research Group, Institute of Inflammation and Ageing, United Kingdom, Birmingham, United Kingdom, ⁶Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁷2nd Department of Medicine, Hietzing Hospital, Vienna, Austria, ⁸Department of Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ⁹Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria
Background/Purpose: Anti-acetylated-peptide antibodies (AAPA) have recently been described in rheumatoid arthritis (RA) patients and may be used as a further diagnostic marker in patients with…
Abstract Number: 1302 • 2016 ACR/ARHP Annual Meeting
Silent Progression in Patients with Rheumatoid Arthritis: Is DAS28 Remission an Insufficient Goal in RA? Results from the German Remission-PLUS Cohort
Dr. Philipp Sewerin¹, PD Dr. Stefan Vordenbäumen¹, Annika Hoyer², Ralph Brinks¹, Dr. Christian Buchbender³, Dr. Christoph Schleich⁴, Sabine Kamp¹, Prof. Dr. Gerald Antoch³, Prof. Dr. Matthias Schneider¹ and Prof. Dr. Benedikt Ostendorf¹, ¹Department of Rheumatology & Hiller Research Unit, Heinrich-Heine University, Düsseldorf, Germany, ²Institute for Biometry and Epidemiology, German Diabetes Center, Duesseldorf, Germany, ³Diagnostic and Interventional Radiology, Heinrich-Heine-University, Düsseldorf, Germany, ⁴Dep. for diagnostic and interventional Radiology, Heinrich-Heine-University, Duesseldorf, Germany
Background/Purpose: disease activity score in 28 joints; Methods: Data-sets of 80 RA patients from the REMISSION-plus study cohort who fulfilled the following criteria were retrospectively…
Abstract Number: 1596 • 2016 ACR/ARHP Annual Meeting
Comparative Effectiveness of Tocilizumab Monotherapy with Tumor Necrosis Factor Inhibitors in Combination with Methotrexate in Patients with Rheumatoid Arthritis and Prior Exposure to Tumor Necrosis Factor Inhibitors
Leslie R. Harrold^1,2, George W. Reed^1,2, Jennie Best³, Steve Zlotnick³, Gioia Persuitte² and Joel M. Kremer⁴, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC, Southborough, MA, ³Genentech, Inc., South San Francisco, CA, ⁴The Albany Medical College, Albany, NY
Background/Purpose: Clinical studies have demonstrated the superior efficacy of tocilizumab monotherapy (TCZ mono) to tumor necrosis factor inhibitor (TNFi) monotherapy and the comparable efficacy of…
Abstract Number: 1605 • 2016 ACR/ARHP Annual Meeting
Pooled Safety and Efficacy of Sarilumab in Rheumatoid Arthritis Patients 65 Years of Age and Older
Roy Fleischmann¹, Mark C. Genovese², Janet van Adelsberg³, Erin Mangan⁴, Melitza Iglesias-Rodriguez⁵, Deborah Dukovic⁶ and TWJ Huizinga⁷, ¹Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ²Stanford University Medical Center, Palo Alto, CA, ³Clinical Science, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Sanofi Genzyme, Cambridge, MA, ⁶Sanofi Genzyme, Bridgewater, NJ, ⁷Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. Sarilumab (150 or 200 mg every 2 weeks [q2w] subcutaneously) + MTX demonstrated efficacy vs placebo…
Abstract Number: 1632 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Sarilumab in Subgroups of Patients with Rheumatoid Arthritis from 2 Phase 3 Studies
Mark C. Genovese¹, Roy Fleischmann², Erin Mangan³, Janet van Adelsberg⁴, Melitza Iglesias-Rodriguez⁵, Deborah Dukovic⁶, Chunpeng Fan⁷ and Tom WJ Huizinga⁸, ¹Stanford University Medical Center, Palo Alto, CA, ²Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Clinical Science, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Sanofi Genzyme, Cambridge, MA, ⁶Sanofi Genzyme, Bridgewater, NJ, ⁷Biostatistics, Sanofi Genzyme, Bridgewater, NJ, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. Efficacy of sarilumab + MTX was demonstrated in patients with RA and inadequate response to MTX…
Abstract Number: 609 • 2015 ACR/ARHP Annual Meeting
A Reduction in Serum Uric Acid Levels May be Related to Methotrexate Efficacy in Early Rheumatoid Arthritis: Data from a Canadian Arthritis Cohort
Jason Lee¹, VP Bykerk², George Dresser³, Gilles Boire⁴, Boulos Haraoui⁵, Carol Hitchon⁶, J Carter Thorne², Diane Tin⁷, Shahin Jamal⁸, Edward C. Keystone⁹, Janet E. Pope¹⁰ and CATCH Investigators, ¹Rheumatology, Western University, St. Joseph's Hospital, London, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Clinical Pharmacology and Toxicology, Western University, London, ON, Canada, ⁴Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Institut de Rhumatologie, Montreal, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸Vancouver Coastal Health, Vancouver, BC, Canada, ⁹Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁰Monsignor Roney Bldg/Rheum, University of Western Ontario, St Joseph Health Care, London, ON, Canada
Background/Purpose: The mechanism of methotrexate in rheumatoid arthritis (RA) is complex. It may increase adenosine levels by blocking conversion to of xanthine to uric acid…
Abstract Number: 3194 • 2015 ACR/ARHP Annual Meeting
Oral to Subcutaneous Methotrexate Dose-Conversion Strategies in the Treatment of Rheumatoid Arthritis
Michael Schiff¹ and Peter Sadowski², ¹Division of Rheumatology, University of Colorado, Denver, CO, ²Antares Pharma Inc., Minneapolis, MN
Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) therapy1 but absorption saturation limitations compromise oral MTX bioavailability (BA). Subcutaneous (SC) MTX has a…
Abstract Number: 1024 • 2015 ACR/ARHP Annual Meeting
Disruptions in Folate Homeostasis May Lead to Increased Risk for Methotrexate Intolerance in Juvenile Idiopathic Arthritis
Mara L Becker¹, Leon van Haandel², Ryan Funk³, Rodger Gaedigk⁴ and J.S. Leeder⁵, ¹Rheumatology, Children's Mercy Kansas City, Kansas City, MO, ²Clinical Pharmacology, Medical Toxicology, and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, MO, ³University of Kansas Medical Center, Kansas City, KS, ⁴Clinical Pharmacology, medical Toxicology and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, MO, ⁵Clinical Pharmacology, Medical Toxicology and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, MO
Background/Purpose: Despite widespread use, there remain no clear predictors of methotrexate (MTX) response or toxicity in Juvenile Idiopathic Arthritis (JIA). With the utilization of new…
Abstract Number: 3197 • 2015 ACR/ARHP Annual Meeting
Clinical Practice Experience in Rheumatoid Arthritis Patients Treated with Triple Therapy and Methotrexate-Tumor Necrosis Factor Inhibition Differs from That of Randomized Controlled Trials
Daniel Erhardt¹, Brian Sauer², Chia-Chen Teng³, Ted R. Mikuls⁴, Jeffrey R. Curtis⁵, Derek Tang⁶, Bradley S. Stolshek⁶ and Grant W. Cannon¹, ¹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Recently published randomized controlled trials (RCTs) have demonstrated similar outcomes in rheumatoid arthritis (RA) patients treated with triple therapy [methotrexate (MTX), sulfasalazine (SUL) and…
Abstract Number: 1039 • 2015 ACR/ARHP Annual Meeting
The Safety and Effect on Disease Activity of Tocilizumab in Combination with MTX Versus Tocilizumab Monotherapy in Patients with Mild to Moderate RA: An Attempt to Optimise the Treatment Response
Burkhard Leeb^1,2, Raimund Lunzer³, Peter Fasching⁴, Manfred Herold⁵, O. Zamani⁶, Winfried Graninger⁷ and OPTIMISE trial Investigators, ¹2nd Dept. of Medicine, State Hospital Stockerau, Center for Rheumatology Lower Austria, Stockerau, Austria, ²Department of Clinical Rheumatology, Karl Landsteiner Society, Stockerau, Austria, ³Department of Internal Medicine, Hospital Barmherzige Brüder Graz-Eggenberg, Graz, Austria, ⁴Department of Internal Medicine V, Wilhelminen Hospital Vienna, Vienna, Austria, ⁵Internal Medicine VI, Medical University of Innsbruck, Austria, Innsbruck, Austria, ⁶Rheumazentrum Favoriten, Wien, Austria, ⁷Rheumatology and Immunology, Medical University of Graz, Graz, Austria
Background/Purpose: An Austrian multi-center study of the effect on disease activity and the safety of Tocilizumab (TCZ) in combination with Methotrexate (MTX) versus TCZ Monotherapy…
Abstract Number: 3239 • 2015 ACR/ARHP Annual Meeting
Response to Methotrexate Predicts Mortality in Rheumatoid Arthritis up to 30 Years
Carolin Krause¹, Siegfried Wassenberg², Rolf Rau³, Gertraud Herborn⁴, Juergen Braun⁵ and Dietmar Krause⁶, ¹University Munster, Munster, Germany, ²Rheumaklinik, Themistocles Gluck hospital - Rheumazentrum Ratingen, Ratingen, Germany, ³Expert in Rheumatology, Düsseldorf, Germany, ⁴Evangelisches Fachkrankenhaus Ratingen, Ratingen, Greece, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶Dept. for Medical Informatics, Biometry and Epidemiology, Ruhr University, Bochum, Germany
Background/Purpose: Methotrexate (MTX) is considered as the anchor drug for the treatment of patients with rheumatoid arthritis (RA). MTX has been shown to reduce disease…
Abstract Number: 1041 • 2015 ACR/ARHP Annual Meeting
Methotrexate Monotherapy and Methotrexate Combination Therapy with Traditional and Biologic Dmards for Rheumatoid Arthritis: A Cochrane Systematic Review and Network Meta-Analysis
Glen S. Hazlewood^1,2, Cheryl Barnabe³, George A. Tomlinson⁴, Deborah Marshall⁵, Daniel Devoe⁵ and Claire Bombardier⁶, ¹Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶18 Strathearn Blvd, University of Toronto, Toronto, ON, Canada
Background/Purpose: To compare methotrexate based disease-modifying anti-rheumatic drug (DMARD) treatments for rheumatoid arthritis in patients naïve to or after an inadequate response (IR) to methotrexate. …
Abstract Number: 3247 • 2015 ACR/ARHP Annual Meeting
Dietary Intake of Omega-3 Fatty Acids and Vitamin C and D Associate with Decreased Pain, Independent of Inflammation, in MTX Treated Early RA Patients
Cecilia Lourdudoss¹, Alicja Wolk², Lars Alfredsson³, Lars Klareskog⁴, Ronald F. van Vollenhoven⁵ and Jon Lampa⁶, ¹Dept. of Medicine, ClinTRID, Karolinska institutet, Stockholm, Sweden, ²Institute of Environmental Medicine (IMM), Karolinska institutet, Stockholm, Sweden, ³The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Karolinska University Hospital, Stockholm, Sweden, ⁵Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ⁶Dep of Medicine, Rheumatology unit, Karolinska Institute, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Chronic pain is common in RA and considered as the major disease burden from the patients’ perspective. Earlier data suggest that omega-3 fatty acids,…

« Previous Page
1
…
6
7
8
9
10
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].